ERBB2 and breast cancer: Finally, it was found that growth of tumors formed by ErbB2-positive breast cancer cells injected in immunodeficient mice is blocked by trastuzumab significantly more efficiently if the drug is administered immediately after cell injection (before the tumor mass is formed) compared to the situation when the drug is administered after a tumor mass is established [47].